Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Han BiomedicalROCO:6999 +0.52%24 Return-on-Tangible-Equity is 9.97% as of Dec. 2025, which is 6% below its 10-year median of 10.64. GuruFocus rates ROCO:6999 with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 1,199 Biotechnology companies, Han Biomedical ranks better than 85.74% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Han Biomedical's annualized net income for the quarter that ended in Dec. 2025 was NT$25.3 Mil. Han Biomedical's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$253.9 Mil. Therefore, Han Biomedical's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 9.97%.
The historical rank and industry rank for Han Biomedical's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:6999'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.68 Med: 10.64 Max: 10.96
Current: 8.94
During the past 5 years, Han Biomedical's highest Return-on-Tangible-Equity was 10.96%. The lowest was 7.68%. And the median was 10.64%.
ROCO:6999's Return-on-Tangible-Equity is ranked better than 85.74% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs ROCO:6999: 8.94
Han Biomedical (ROCO:6999) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Han Biomedical Return-on-Tangible-Equity Related Terms
Han Biomedical Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Han Biomedical's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6999 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Han Biomedical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Han Biomedical Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Han Biomedical's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Han Biomedical's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 9.97% mean?
Han Biomedical (ROCO:6999) has a Return-on-Tangible-Equity of 9.97% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Han Biomedical and its competitors. This is near median its historical median of 10.64. Over the past decade, Han Biomedical's Return-on-Tangible-Equity has ranged from 7.68 to 10.96. According to the industry distribution chart, Han Biomedical ranks #171 out of 1199 companies in the Biotechnology industry, placing it in the top 14.3%.
Is Han Biomedical's Return-on-Tangible-Equity too high?
Han Biomedical's current Return-on-Tangible-Equity of 9.97% is near median its 10-year median of 10.64. Over the past 10 years, this metric has ranged from a low of 7.68 to a high of 10.96. Based on the distribution chart, Han Biomedical ranks #171 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Han Biomedical has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Han Biomedical's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Han Biomedical ranks #171 out of 1199 companies for Return-on-Tangible-Equity. This places Han Biomedical in the top 14% of its industry — outperforming the majority of peers. Historically, Han Biomedical's own Return-on-Tangible-Equity has ranged from 7.68 to 10.96 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Han Biomedical and its competitors. Han Biomedical's current Return-on-Tangible-Equity is 9.97%, which is near median its own 10-year median of 10.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Han Biomedical stock overvalued right now?
Han Biomedical (ROCO:6999) has a current Return-on-Tangible-Equity of 9.97%. The current Return-on-Tangible-Equity is 9.97%, which is near median its 10-year median of 10.64. Han Biomedical's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Han Biomedical (ROCO:6999), the current Return-on-Tangible-Equity is 9.97% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6999 has been successfully added to your 
